Core Viewpoint - The A-share market experienced a significant decline on September 4, with the Sci-Tech 50 index dropping over 7%, indicating a bearish trend in the market [1][2]. Group 1: Market Performance - The Sci-Tech 50 index closed at 1212.05, down 94.43 points or 7.23% from the previous close of 1306.48 [3]. - The trading volume for the Sci-Tech 50 index was 14.08 billion, with a total transaction value of 832.70 billion [3]. - The index reached a high of 1304.05 and a low of 1211.02 during the trading session [3]. Group 2: Key Stocks Performance - Major constituent stocks of the Sci-Tech 50 index saw significant declines, with Cambrian falling over 15% to 1189.02, a decrease of 215.9 points [4]. - Other notable declines included Huatai Medical down 4.31% to 301.81, Kingsoft down 7.37% to 290.85, and Zhaojin Technology down 4.14% to 200.30 [4]. - The overall trend showed that 552 stocks declined, while only 34 stocks increased, indicating a broad market downturn [3].

每经AI快讯，华源证券9月3日发布研报称，给予联影医疗（688271.SH，最新价：140.88元）买入评 级。评级理由主要包括：1）国内经营回暖，海外维持快速增长；2）毛利率小幅调整，创新产品获批行 业影响力持续提升。风险提示：并购整合不及预期风险、海外地缘政治风险、国内政策风险、新品推广 不及预期风险。 每经头条（nbdtoutiao）——AI内容强制标识"首周"实测：抖音、小红书、微博自动识别"失灵"，AI应 用文本漏标，视频"会员可去水印" （记者 谭玉涵） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 ...

Market Overview - The A-share market experienced a significant decline, with major indices continuing to drop on September 4th [2] - The Shanghai Composite Index closed at 3734.20, down 79.36 points or 2.08% [3] - The Shenzhen Component Index fell by 493.1 points, a decrease of 3.95%, closing at 11978.81 [3] - The ChiNext Index saw a decline of 5.36%, closing at 2744.03 [3] Sector Performance - The STAR 50 Index (科创50) dropped over 7%, with major constituent stocks like Cambrian (寒武纪) falling more than 15% [3][6] - The overall trading volume in the A-share market was reported at 418.2 billion [3] Key Stock Movements - Cambrian (688256) saw a significant drop of 15.37%, closing at 1189.02 [6] - Other notable declines included Baillie Gifford (688506) down 7.22% and Huatai Medical (688617) down 4.31% [6] - The STAR 50 Index's performance reflects broader market trends, with a year-to-date decline of 14.54% [4]

联影医疗（688271.SH） 国内市场稳健增长，海外市场表现亮眼，AI 赋能战略坚定推进 证券研究报告 | 半年报点评 gszqdatemark 2025 09 04 年 月 日 联影医疗发布 2025 年半年度报告。2025H1 公司实现营业收入 60.16 亿元，同比增长 12.79%；归母净利润 9.98 亿元，同比增长 5.03%；扣非后归母净利润 9.66 亿元，同比增 长 21.01%。分季度看，2025Q2 实现营业收入 35.38 亿元，同比增长 18.60%；归母净利润 6.28 亿元，同比增长 6.99%；扣非后归母净利润 5.87 亿元，同比增长 17.96%。 观点：招采需求稳步复苏，设备与服务协同增长，MR、XR 等产品增长靓丽，重点产品线海 内外市场均有所突破。海外市场高速增长，高端市场与新兴市场均有所突破。AI 已赋能至 各产品线，助力产品力提升，国产医学影像龙头强者恒强。 招采需求逐步复苏，公司业绩稳健增长，服务业务表现亮眼。2025H1公司实现设备收入48.90 亿元（同比+7.61%），服务收入 8.16 亿元（同比+32.21%），随着招采活动稳步恢复，设备 与服务协同 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) due to the recovery of domestic business and continuous breakthroughs in innovative products [5]. Core Views - The company reported a revenue of 6.016 billion yuan for the first half of 2025, representing a year-on-year increase of 12.79%, and a net profit attributable to shareholders of 999.8 million yuan, up 5.03% year-on-year [7]. - The domestic revenue reached 4.873 billion yuan, with a year-on-year growth of 10.74%, while overseas revenue was 1.142 billion yuan, growing by 22.48% year-on-year [7]. - The overall gross margin for the first half of 2025 was 47.93%, a decrease of 2.44 percentage points year-on-year, with service business gross margin remaining above 60% [7]. - The company is expected to achieve revenues of 12.604 billion yuan, 15.157 billion yuan, and 18.224 billion yuan for 2025, 2026, and 2027 respectively, with corresponding year-on-year growth rates of 22.37%, 20.25%, and 20.24% [6][7]. Financial Performance Summary - For 2025, the company is projected to have a net profit attributable to shareholders of 1.871 billion yuan, with a year-on-year growth of 48.26% [6]. - The earnings per share (EPS) for 2025 is estimated at 2.27 yuan, with a projected price-to-earnings (P/E) ratio of 65.57 [6][9]. - The company’s total market capitalization is approximately 122.67 billion yuan, with a closing price of 148.84 yuan [3].

Group 1 - The core viewpoint of the news is that 联影医疗 (United Imaging Healthcare) experienced a decline in stock price, dropping by 5.01% to 141.39 yuan per share, with a trading volume of 715 million yuan and a turnover rate of 0.60%, resulting in a total market capitalization of 116.528 billion yuan [1] - 联影医疗, established on March 21, 2011, and listed on August 22, 2022, specializes in high-performance medical imaging equipment, radiation therapy products, life science instruments, and medical digital and intelligent solutions [1] - The company's revenue composition includes 81.99% from sales of medical imaging diagnostic equipment and radiation therapy equipment, 13.16% from maintenance services, 4.04% from other sources, and 0.81% from software [1] Group 2 - From the perspective of fund holdings, 国联基金 (Guolian Fund) has one fund heavily invested in 联影医疗, specifically the 国联上证科创板综合指数增强A (023911), which held 8,800 shares, accounting for 0.22% of the fund's net value, ranking as the ninth largest holding [2] - The fund has a current scale of 430 million yuan and has achieved a return of 24.31% since its inception on June 4, 2025 [2] - The fund managers, 王喆 and 黄磊鑫, have different tenures and performance records, with 王喆 having a tenure of 6 years and 295 days, managing assets totaling 1.657 billion yuan, and 黄磊鑫 with a tenure of 147 days managing 831 million yuan [2]

Summary of Key Points Core Viewpoint - In the past five trading days, a total of 504 companies were investigated by institutions, with notable interest in companies like Mindray Medical, United Imaging Healthcare, and Aibo Medical, indicating a trend of institutional focus on specific healthcare and technology sectors [1]. Institutional Research Activity - 95.63% of the companies investigated had participation from securities firms, with 482 companies being surveyed by them. Fund companies followed with 415 companies, and private equity firms investigated 303 companies [1]. - Among the companies, 269 received attention from more than 20 institutions, with Mindray Medical being the most investigated at 398 institutions, followed by United Imaging Healthcare at 306 institutions, and Aibo Medical at 262 institutions [1]. Fund Flow and Market Performance - Out of the stocks investigated by more than 20 institutions, 65 experienced net capital inflows in the past five days. Unisplendour saw the highest net inflow of 1.259 billion yuan, followed by Shenghong Technology and Changchun High-tech with net inflows of 1.231 billion yuan and 616 million yuan, respectively [1]. - In terms of market performance, 94 stocks among those investigated saw price increases, with the highest gains recorded by Bojie Co., Yuanjie Technology, and Tengjing Technology, with increases of 37.99%, 34.58%, and 34.14% respectively. Conversely, 175 stocks experienced declines, with the largest drops seen in Oulu Tong, Zhiyuan Huilian, and Sanhui Electric, with decreases of 16.61%, 14.80%, and 14.78% respectively [2]. Earnings Forecasts - Among the stocks investigated, only two companies released earnings forecasts for the first three quarters, both indicating profit increases. Zhongtai Co. is expected to have a median net profit of 340 million yuan, representing a year-on-year increase of 79.28% [2].

Group 1 - A significant decrease in the number of shareholders often indicates a concentration of shares, which attracts market attention [1] - According to statistics, 241 stocks experienced a decline in shareholder numbers exceeding 20% compared to the end of the first quarter, with 77 stocks seeing a decline of over 30% [1] - Among non-ST stocks, Tianpu Co., Development Technology, and Zhejiang Huaye saw declines exceeding 50% [1] Group 2 - The mechanical industry has the highest number of concentrated stocks, totaling 38, followed by the basic chemical industry with 19 [1] - The electronics, automotive, and pharmaceutical industries each have 16 stocks with a decline in shareholder numbers exceeding 20% [1] - Concentrated stocks have generally performed well, with an average increase of 19.32% since July, outperforming the CSI 300 index by approximately 6 percentage points [1] Group 3 - Among the concentrated stocks, Tianpu Co., Zhongji Xuchuang, and Industrial Fulian have seen significant cumulative gains, with their stock prices doubling [1] - Of the 241 concentrated stocks, 65 have been subject to institutional research since July, with nine stocks receiving attention from over 100 research institutions [1] - Institutions are particularly focused on the overall performance of listed companies in the first half of the year and their outlook for the second half [1]

August 31, 2025 04:14 PM GMT Shanghai United Imaging Healthcare Co | Asia Pacific 2Q Above MSe; Accelerated 2H Growth Seen Driven by Policy Tailwinds, Innovative Initiatives, Global Expansion Reaction to earnings Unchanged Modest upside Modest revision higher Impact to our thesis Financial results versus consensus Direction of next 12-month Source: Company data, Morgan Stanley Research Key Takeaways Equipment "trade-in": The MoF announced a Rmb188bn ultra-long STB for 2025's "equipment trade-in" program. Ma ...

Core Insights - The healthcare industry is undergoing a transformation driven by disruptive technologies such as artificial intelligence and precision medicine, evolving from single diagnostic equipment innovation to a comprehensive digital health management ecosystem covering prevention, diagnosis, treatment, and rehabilitation [1] - The global medical device market is expanding, with a projected growth from over $480 billion in 2021 to $848 billion by 2030, indicating a compound annual growth rate of 6.4% from 2021 to 2030, providing ample opportunities for leading companies [2] - Domestic medical device manufacturers, including United Imaging Healthcare, are gaining market share and improving product quality, with the company achieving a 3.4 percentage point increase in its market share in the medical imaging and radiation therapy equipment sector [3][4] Company Performance - United Imaging Healthcare reported a revenue of 6.016 billion yuan for the first half of 2025, a year-on-year increase of 12.79%, and a net profit of 966 million yuan, up 21.01% year-on-year [1] - The company has implemented a cash dividend plan, distributing 1.3 yuan per 10 shares to shareholders, totaling 107 million yuan, and launched a new stock incentive plan for 1,368 key personnel [1] - The company’s revenue from the Chinese market reached 4.873 billion yuan, reflecting a growth of 10.74% amid the domestic upgrade of medical imaging equipment [5] Product and Market Development - United Imaging Healthcare's MR equipment generated 1.968 billion yuan in revenue, a 16.81% increase, with significant advancements in MR technology leading to a market share increase of over 20 percentage points [3] - The CT business maintained steady growth with revenue of 1.515 billion yuan, while the MI products achieved 841 million yuan in revenue, a 13.15% increase [4] - The company’s service business grew by 32.21% to 816 million yuan, accounting for 13.56% of total revenue, enhancing customer loyalty and market competitiveness [4] Global Expansion - United Imaging Healthcare's overseas revenue reached 1.142 billion yuan, a 22.48% increase, constituting 18.99% of total revenue, with expectations for continued growth in the second half of the year [7] - The company has successfully penetrated the North American market, with its high-end imaging equipment covering over 70% of U.S. states and achieving significant installations in top research and clinical institutions [7][8] - In emerging markets, the company has seen substantial growth, with orders and revenue increasing significantly in Latin America and Africa, establishing a regional office in Brazil to enhance market presence [8][9] Technological Innovation - United Imaging Healthcare invested 766 million yuan in R&D during the first half of 2025, with a research expense ratio of 12.74%, focusing on next-generation platform technologies [11] - The company has filed over 260 new patent applications, with a total of over 9,700 patent applications, including significant advancements in AI and imaging technology [11][12] - The introduction of the uCT SiriuX, a dual-source CT system, and the uIPW intelligent contouring system for radiation therapy highlights the company's commitment to innovation and leadership in the medical imaging field [12][13]